Chemcrux Enterprises reported a 135% year-on-year increase in standalone net profit to ₹137.43 lakh for the quarter ended June 30, 2026, driven by a 31% surge in revenue from operations. The Vadodara-based bulk drug intermediate manufacturer saw its consolidated net profit attributable to owners jump 444% to ₹50.52 lakh during the same period, signaling robust operational scaling and improved bottom-line efficiency.

The Board of Directors approved these unaudited financial results on August 4, 2026, alongside the Limited Review Report from statutory auditors Naresh & Co. The company’s total comprehensive income for the quarter reached ₹159.22 lakh on a standalone basis and ₹72.31 lakh on a consolidated basis, which includes wholly-owned subsidiary Kalichem Private Limited.

Financial Performance Highlights

Revenue from operations stood at ₹2,193.81 lakh on a standalone basis, up from ₹1,674.74 lakh in the corresponding quarter of FY26. On a consolidated basis, revenue was ₹2,193.82 lakh, compared to ₹1,650.35 lakh in Q1FY26. The improvement in profitability was supported by controlled cost structures despite higher material consumption. Standalone cost of materials consumed rose to ₹827.51 lakh from ₹552.72 lakh in Q1FY25, while employee benefits expense increased to ₹259.05 lakh from ₹201.99 lakh. Other expenses remained stable at ₹655.12 lakh compared to ₹434.79 lakh in the previous year.

Basic earnings per share (EPS) improved to ₹0.93 from ₹0.39 on a standalone basis. Consolidated basic EPS rose to ₹0.34 from ₹0.06. Diluted EPS remained identical to basic EPS due to the negligible impact of employee stock options, as disclosed under Ind AS 33.

Corporate Governance and Disclosures

The Board meeting, held at the company’s registered office in Vadodara, also scheduled the 30th Annual General Meeting for September 17, 2026, via video conferencing. Dipika Rajpal, Company Secretary & Compliance Officer, signed the disclosure submitted to BSE Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Naresh & Co., Chartered Accountants, issued their limited review report stating that nothing came to their attention to suggest the statements contained material misstatements. The audit covered both standalone and consolidated results, including procedures for the subsidiary Kalichem Private Limited.

What the Numbers Show

The significant divergence between standalone and consolidated profit growth warrants attention. While standalone PAT surged 135%, consolidated PAT jumped over 440%. This suggests that the subsidiary, Kalichem Private Limited, may have contributed disproportionately to the bottom-line improvement or benefited from specific one-time gains not reflected in the parent entity’s standalone figures. Additionally, the company granted 1,07,700 Employee Stock Options on May 15, 2026, under the ESOP 2025 Scheme, with associated expenses recognized in the current quarter. The implementation of the New Labour Codes effective November 21, 2025, did not materially impact the financial results, as employee benefit structures were already aligned with the new framework.

Chemcrux Enterprises has accepted the resignation of Sidhdhi Girishkumar Shah from its Board of Directors, effective August 4, 2026. The departure of a board member may impact committee compositions and governance oversight, though the company stated there are no undisclosed material reasons behind the exit.

The Board approved the acceptance during a meeting held at its registered office in Vadodara on Tuesday, August 4, 2026. The session commenced at 5:00 PM and concluded at 7:20 PM. In compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Circular no. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, the company issued a formal disclosure to the BSE Limited.

Sidhdhi Girishkumar Shah served as a Non-Executive, Non-Independent Director. Her resignation letter, dated August 4, 2026, cites pre-occupation as the primary reason for stepping down. She also resigned from her role as Chairperson of the Stakeholders Relationship Committee concurrently with her board exit.

The company confirmed that Mrs. Shah does not hold any directorship or membership in the board committees of other listed entities as of the date of resignation. Furthermore, she affirmed that no other material reasons influenced her decision to leave the board beyond those explicitly stated in her resignation letter.

Resignation Details

The acceptance was formally signed by Dipika Rajpal, Company Secretary & Compliance Officer, on behalf of Chemcrux Enterprises Limited.